| 1 |
33509790 | Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. | 2021 Apr |
1 |
| 2 |
33811972 | Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. | 2021 Jun |
3 |
| 3 |
33901462 | JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. | 2021 Jul 5 |
1 |
| 4 |
34440089 | Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. | 2021 Jul 24 |
3 |
| 5 |
31968212 | JAK-STAT-dependent regulation of scavenger receptors in LPS-activated murine macrophages. | 2020 Mar 15 |
1 |
| 6 |
29295936 | Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. | 2018 Jan 16 |
1 |
| 7 |
28405527 | JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. | 2017 |
1 |
| 8 |
27222478 | Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. | 2016 Jul 7 |
1 |